Refine Search

Search Results -

Terms	Documents
L11 same L3	32

Database:
US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search: L12

Refine Search

Recall Text | Clear | Interrupt

Search History

DATE: Monday, March 01, 2004 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT; PLUR=YES; OP=ADJ			
L12	L11 same l3	32	L12
L11	il-6 same (l1 or l5) same l7	95	L11
L10	L9 and l8	48	L10
L9	il-6	4419	L9
L8	L7 and l6	69	L8
L7	bone	66866	L7
L6	L5 same l3	102	L6
L5	anti-cytokine	207	L5
L4	L3 same l2 same l1	2074	L4
L3	in vivo or therapy or inhibit$	422134	L3
L2	cytokine or cytokines	17324	L2
L1	antibody or antibodies	67564	L1

END OF SEARCH HISTORY

```
4994 S IL-11 OR INTERLEUKIN-11
L2          673 S L1 (P) ANTIBOD?
L3          404 S L2 (P) (ADMINIST? OR THERAP? OR TREAT? OR METHOD?)

=> s l1 (5a) antibod?
L4          89 L1 (5A) ANTIBOD?

=> s l4 (5a) (administ? or therap? or treat? or method?)
L5           9 L4 (5A) (ADMINIST? OR THERAP? OR TREAT? OR METHOD?)

=> d l5 1-9 bib kwic

L5   ANSWER 1 OF 9     MEDLINE on STN
AN   2002322722     MEDLINE
DN   PubMed ID: 12065535
TI   Contribution of interleukin-11 and prostaglandin(s) in
     lipopolysaccharide-induced bone resorption in vivo.
AU   Li Li; Khansari Alireza; Shapira Lior; Graves Dana T; Amar Salomon
CS   Department of Periodontology and Oral Biology, School of Dental Medicine,
     Boston University, Boston, Massachusetts 02118, USA.
NC   12482 (NIDCR)
     DE07559
SO   Infection and immunity, (2002 Jul) 70 (7) 3915-22.
     Journal code: 0246127. ISSN: 0019-9567.
CY   United States
DT   Journal; Article; (JOURNAL ARTICLE)
LA   English
FS   Priority Journals
EM   200207
ED   Entered STN: 20020615
     Last Updated on STN: 20020731
     Entered Medline: 20020730
AB   . . . lacking IL-1 receptor type I (IL-1RI(-/-)), mice lacking TNF
     receptor p55 and IL-1RI (TNFRp55(-/-)-IL-1RI(-/-)), and wild-type mice.
     Mice were then treated with injections of anti-IL-
     11 monoclonal antibody (MAb), indomethacin, or
     phosphate-buffered saline (PBS) and sacrificed 5 days later. Histological
     sections stained for tartrate-resistant acid phosphatase (TRAP) were. .
     .

L5   ANSWER 2 OF 9     MEDLINE on STN
AN   1999069250     MEDLINE
DN   99069250   PubMed ID: 9767454
TI   An anti-inflammatory role for interleukin-11 in established murine
     collagen-induced arthritis.
AU   Walmsley M; Butler D M; Marinova-Mutafchieva L; Feldmann M
CS   Kennedy Institute of Rheumatology, London, UK.
SO   IMMUNOLOGY, (1998 Sep) 95 (1) 31-7.
     Journal code: 0374672. ISSN: 0019-2805.
CY   ENGLAND: United Kingdom
DT   Journal; Article; (JOURNAL ARTICLE)
LA   English
FS   Priority Journals
EM   199901
ED   Entered STN: 19990209
     Last Updated on STN: 19990209
     Entered Medline: 19990128
AB   . . . of IL-11 that the anticollagen type II (CII) response may have
     been augmented, there was no statistically significant effect of
     IL-11 treatment on anti-CII antibody
     levels. Similarly, the acute-phase reactant serum amyloid P was only
     elevated in mice receiving very high doses (50-100 microgram/day) of. .
     .
```

L5 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:965157 CAPLUS
DN 138:38076
TI WSX receptor agonist antibodies for treating diseases associated with lymphopoiesis, erythropoiesis, myelopoiesis, and obesity
IN Carter, Paul J.; Chiang, Nancy Y.; Kim, Kyung Jin; Matthews, William; Rodrigues, Maria L.
PA USA
SO U.S. Pat. Appl. Publ., 140 pp., Cont.-in-part of U.S. Ser. No. 667,197.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002193571	A1	20021219	US 1997-779457	19970107
	CA 2241564	AA	19970717	CA 1997-2241564	19970107
	ZA 9700148	A	19980708	ZA 1997-148	19970108
	US 6541604	B1	20030401	US 1997-780562	19970108
	US 2003004109	A1	20030102	US 2002-214802	20020806
PRAI	US 1996-585005	B2	19960108		
	US 1996-667197	A2	19960620		
	US 1996-64855P	P	19960108		
	US 1997-780562	A3	19970108		

IT Cytokines
Interleukin 1
Interleukin 10
Interleukin 11
Interleukin 2
Interleukin 3
Interleukin 4
Interleukin 5
Interleukin 6
Interleukin 7
Interleukin 8
Interleukin 9
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(WSX receptor **antibodies** for **treating** diseases associated with lymphopoiesis, erythropoiesis, myelopoiesis, and obesity)

L5 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:489736 CAPLUS
DN 137:183745
TI Contribution of interleukin-11 and prostaglandin(s) in lipopolysaccharide-induced bone resorption in vivo
AU Li, Li; Khansari, Alireza; Shapira, Lior; Graves, Dana T.; Amar, Salomon
CS Department of Periodontology and Oral Biology, School of Dental Medicine, Boston University, Boston, MA, 02118, USA
SO Infection and Immunity (2002), 70(7), 3915-3922
CODEN: INFIBR; ISSN: 0019-9567
PB American Society for Microbiology
DT Journal
LA English
RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT
AB We previously demonstrated that interleukin-1 (IL-1) and tumor necrosis factor (TNF) activities only partially account for calvarial bone resorption induced by local application of lipopolysaccharide (LPS) in mice. The present study was undertaken to determine the role and relative contribution of IL-11 and prostaglandin(s) (PG[s]) in LPS-induced bone resorption in vivo. A one-time dose of LPS was injected into the s.c. tissue overlying calvaria of mice lacking IL-1 receptor type I (IL-1RI-/-), mice lacking TNF receptor p55 and IL-1RI (TNFRp55-/--IL-1RI-/-), and wild-type mice. Mice were then **treated** with injections

of anti-**IL-11** monoclonal **antibody** (MAb), indomethacin, or phosphate-buffered saline (PBS) and sacrificed 5 days later. Histol. sections stained for tartrate-resistant acid phosphatase (TRAP) were quantified by histomorphometric anal. At low doses of LPS (100 μg/mouse), the percentages of bone surface covered by osteoclasts were found to be similar in three strains of mice. The increase was reduced by 37% with anti-IL-11 MAb and by 46% with indomethacin. At higher doses of LPS (500 μg/mouse), we found an eightfold increase in these percentages in wild-type mice and a fivefold increase in these percentages in IL-1RI-/- and TNFRp55-/--IL-1RI-/- mice after normalizing with the value from the saline-PBS control group in the same strain of mice. The increase was reduced by 55 and 69% in wild-type mice and by 50 and 57% in IL-1RI-/- and TNFRp55-/--IL-1RI-/- mice treated with anti-IL-11 MAb or indomethacin, resp. Our findings suggest that in vivo, at low doses of LPS (100 μg/mouse), LPS-induced bone resorption is mediated by IL-11 and PGs, while at high doses of LPS (500 μg/mouse), it is mediated by IL-11, PGs, IL-1, and TNF signaling. IL-11 and PGs mediate LPS-induced bone resorption by enhancing osteoclastogenesis independently of the IL-1 or TNF signaling.

L5 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:101180 CAPLUS
DN 134:161896
TI Mammalian cytokines; related reagents
IN Timans, Jacqueline C.; Kastelein, Robert A.; Bazan, J. Fernando
PA Schering Corporation, USA
SO PCT Int. Appl., 73 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001009176	A2	20010208	WO 2000-US20475	20000727
	WO 2001009176	A3	20011101		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1200592	A2	20020502	EP 2000-950787	20000727
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	JP 2003506026	T2	20030218	JP 2001-513982	20000727
PRAI	US 1999-364674	A	19990730		
	US 1999-369643	A	19990806		
	WO 2000-US20475	W	20000727		

IT **Antibodies**
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(mammalian interleukin 80D and **interleukin 11** for diagnosis and **therapy** of degenerative or abnormal condition of immune system and/or hematopoietic cells)

IT **Antibodies**
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(monoclonal; mammalian interleukin 80D and **interleukin 11** for diagnosis and **therapy** of degenerative or abnormal condition of immune system and/or hematopoietic cells)

L5 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1999:753092 CAPLUS
DN 132:2795
TI Antagonists of interleukin 11-mediated osteoporotic bone loss
IN Shaughnessy, Stephen; Austin, Richard Carl
PA Hamilton Civic Hospital Research Development Corporation, Can.
SO PCT Int. Appl., 61 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9959608	A2	19991125	WO 1999-CA516	19990519
	WO 9959608	A3	20000406		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2328486	AA	19991125	CA 1999-2328486	19990519
	AU 9940277	A1	19991206	AU 1999-40277	19990519
	AU 767749	B2	20031120		
	EP 1079847	A2	20010307	EP 1999-923352	19990519
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002515444	T2	20020528	JP 2000-549272	19990519
PRAI	CA 1998-2237915	A	19980519		
	WO 1999-CA516	W	19990519		

IT **Antibodies**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(neutralizing; to interleukin-11 or **IL-11** receptor for osteoporosis **therapy**)

L5 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:586896 CAPLUS
DN 129:301592
TI An anti-inflammatory role for interleukin-11 in established murine collagen-induced arthritis
AU Walmsley, M.; Butler, D. M.; Marinova-Mutafchieva, L.; Feldmann, M.
CS Kennedy Inst. of Rheumatology, London, UK
SO Immunology (1998), 95(1), 31-37
CODEN: IMMUAM; ISSN: 0019-2805
PB Blackwell Science Ltd.
DT Journal
LA English
RE.CNT 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT
AB Interleukin-11 (IL-11) is a cytokine belonging to the IL-6 family which has both pro- and anti-inflammatory potential. Like IL-6 it can diminish tumor necrosis factor-α and IL-1 production, and augment Ig synthesis. We have explored the immunomodulatory effects of IL-11 treatment in mice in a model of inflammatory autoimmune joint disease, collagen-induced arthritis (CIA). Recombinant human IL-11 was administered at various doses to DBA/1 mice after the onset of CIA. IL-11 treatment caused a significant reduction in the clin. severity established CIA, which was associated with protection from joint damage, as assessed by histol. Although there was a suggestion at high doses of IL-11 that the anticollagen type II (CII) response may have been augmented, there was no statistically significant effect of **IL-11 treatment** on

anti-CII **antibody** levels. Similarly, the acute-phase reactant serum amyloid P was only elevated in mice receiving very high doses (50-100 μg/day) of IL-11. Endogenous IL-11 was abundantly produced in synovial membrane cultures derived from CII-immunized mice with active disease, suggesting that, as in rheumatoid arthritis, this cytokine is spontaneously produced in the inflammatory response in CIA. The results presented here demonstrate an anti-arthritic immunoregulatory role for IL-11 in murine CIA, and suggest that IL-11 is a candidate therapeutic mol. for human inflammatory arthritic diseases.

L5 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1996:681971 CAPLUS
DN 126:6450
TI Anti-gp130 monoclonal antibodies for inflammatory disease treatment
IN Burstein, Samuel A.
PA The Board of Regents of the University of Oklahoma, USA
SO U.S., 14 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5571513	A	19961105	US 1995-455799	19950531
	WO 9638481	A1	19961205	WO 1996-US7385	19960522
	W: AU, CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9658695	A1	19961218	AU 1996-58695	19960522
PRAI	US 1995-455799		19950531		
	WO 1996-US7385		19960522		

IT **Interleukin 11**
Interleukin 6
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(anti-gp130 monoclonal **antibodies** for inflammatory disease **treatment**)

L5 ANSWER 9 OF 9 USPATFULL on STN
AN 2002:19059 USPATFULL
TI Agonist antibodies
IN Adams, Camellia W., Mountain View, CA, United States
Carter, Paul J., San Francisco, CA, United States
Fendly, Brian M., Half Moon Bay, CA, United States
Gurney, Austin L., Belmont, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 6342220 B1 20020129
AI US 1997-918148 19970825 (8)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Nolan, Patrick J.
LREP Piper Marbury Rudnick & Wolfe LLP, Kelber, Steven B.
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 11 Drawing Figure(s); 11 Drawing Page(s)
LN.CNT 4209
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
DETD . . . stimulating factors or interleukins include; kit-ligand, LIF, G-CSF, GM-CSF, M-CSF, EPO, IL-1, IL-2, IL-3, IL-5, IL-6, IL-7, IL-8, IL-9 or **IL-11**. Alternatively, the **antibody** is **administered** in combination with an Insulin-like growth factor (e.g., IGF-1) or a tumor necrosis factor (e.g., lymphotoxin (LT)).